NCT04579640View on ClinicalTrials.gov

Trial of Vitamin D to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections

PHASE3CompletedINTERVENTIONAL
Enrollment

6,200

Participants

Timeline

Start Date

October 27, 2020

Primary Completion Date

June 17, 2021

Study Completion Date

February 28, 2022

Conditions
Covid19Acute Respiratory Tract Infection
Interventions
DIETARY_SUPPLEMENT

Vitamin D

Capsules containing 800 IU (20 micrograms) or 3,200 IU (80 micrograms) cholecalciferol

Trial Locations (1)

E1 2AB

Queen Mary University of London, London

Sponsors

Collaborators (1)

Pharma Nord
All Listed Sponsors
collaborator

Barts & The London NHS Trust

OTHER

collaborator

Pharma Nord

INDUSTRY

collaborator

Fischer Family Trust

UNKNOWN

collaborator

The AIM Foundation

UNKNOWN

collaborator

Synergy Biologics Ltd

UNKNOWN

collaborator

Cytoplan Ltd

UNKNOWN

lead

Queen Mary University of London

OTHER

NCT04579640 - Trial of Vitamin D to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections | Biotech Hunter | Biotech Hunter